Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: MabCampath
Active Ingredient: Alemtuzumab 30mg/mL
Dosage Form: Concentrate for infusion
New Zealand Sponsor: Bayer New Zealand Limited
Manufacturer: Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany
Note: This consent is valid for two years from the date of publication of this notice.
Product: Revatio
Active Ingredient: Sildenafil citrate 28.09mg equivalent to sildenafil 20mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Pfizer New Zealand Limited
Manufacturer: Pfizer PGM, Zone Industrielle, Poce Sur Cisse, France
Note: This consent is valid for two years from the date of publication of this notice.
Product: Sebivo
Active Ingredient: Telbivudine 600mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer: Novartis Pharma Stein AG, Stein, Switzerland
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 16th day of July 2007.
ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).